MMI Co-Founder, John Hipp, PhD. to be Guest Editor for Special Issue of Bioengineering! Submit by Nov 30!
Press Release!: Driving Excellence in Cardiovascular Trials: MMI and Healthcare Inroads Deepen Collaboration
MMI and HCIR continue to expand their combined impact in cardiovascular clinical trials.
MMI Co-Founder and Chief Scientific Officer, Dr. John Hipp, PhD, has been invited to serve as the Guest Editor for an upcoming Special Issue of Bioengineering Journal!
US-based Medical Metrics, Inc. and Japan-based Micron, Inc. are teaming up to create a global imaging core lab offering for clinical trials.
The latest news regarding the 1st AI Platform to look at the dynamic nature of x-rays.
SpineCAMP can provide Actionable Insights related to spinal instability or fusion assessment!
Stop by to learn how SpineCAMP uses AI to analyze X-rays to generate enhanced visualizations & reports, to support clinical assessment of spine health.
https://tech.einnews.com/pr_news/659012865/medical-metrics-inc-hires-dennis-farrell-to-lead-commercialization-of-spinecamp-ai-powered-image-analysis-platform
https://www.einpresswire.com/article/656086444/medical-metrics-inc-announces-latest-510-k-clearance-for-spine-camp-ai-powered-image-analysis-platform
The FDA granted RMAT designation to DiscGenics’ Injectable Disc Cell Therapy for degenerative disc disease.
A newly signed law permits the FDA to clear a drug for human clinical trials while bypassing animal trials.
MMI co-founder, Dr. John Hipp, was recognized for his outstanding contributions to spine basic research.
Ongoing consolidations and investment has prompted strong growth in new technologies for treatment of extremities, including the foot and ankle.